戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 domain, which is able to effectively prolong thrombin time.
2 y of bleeding, is characterized by prolonged thrombin time, abnormal fibrin polymerization, and incre
3    Among 68 patients with an elevated dilute thrombin time and 81 with an elevated ecarin clotting ti
4  dabigatran plasma concentration and diluted thrombin time and ecarin clotting time, and a non-linear
5 ed by the dabigatran-specific assays diluted thrombin time and ecarin clotting time.
6 late (DE) dose-dependently prolonged diluted thrombin time and tail-vein bleeding time, which were re
7  to exosite II of thrombin, prolong both the thrombin time and the activated partial thromboplastin t
8 mes, bilirubin, ammonia levels, prothrombin, thrombin time, and cytokines.
9                                         In a thrombin time assay using purified components, high conc
10 21 patients (97.5%) with an elevated diluted thrombin time at presentation and 95 of 131 patients (72
11                          Reversal of diluted thrombin time (dTT), ecarin clotting time (ECT), activat
12                     For dabigatran, a normal thrombin time excludes clinically relevant drug concentr
13 l thromboplastin time, prothrombin activity, thrombin time, fibrinogen, d-dimer, platelet count, were
14 time, activated partial thromboplastin time, thrombin time, fibrinogen, D-dimer, von Willebrand facto
15  a monoclonal IgG to exosite II prolongs the thrombin time indirectly by accelerating the thrombin-an
16 f purified VN to VN -/- plasma prolonged the thrombin time into the normal range, suggesting that VN
17 brinogen conversion to fibrin as assessed by thrombin time measurements, and thrombin exosite binding
18            Purified fibrinogen prolonged the thrombin time of normal plasma.
19                                          The thrombin time of plasma or purified fibrinogen was prolo
20                                              Thrombin times of plasma from VN -/- mice (20.5 +/- 2.1
21 of idarucizumab, on the basis of the diluted thrombin time or ecarin clotting time.
22 nation at a central laboratory of the dilute thrombin time or ecarin clotting time.
23  to 100), on the basis of either the diluted thrombin time or the ecarin clotting time.
24 of the commonly used tests, such as PT, PTT, thrombin time, platelet count, fibrinogen, and the prese
25                                   The dilute thrombin time (R(2) = 0.92 to 0.99) and ecarin-based ass
26 cofactor II confirm that prolongation of the thrombin time requires antithrombin.
27 ated partial thromboplastin time (aPTT), and thrombin time (TT) were secondary endpoints assessed by
28 ctivated partial thromboplastin time (aPTT), thrombin time (TT), as well as thrombin generation assay
29 ated partial thromboplastin time (APTT), and thrombin time (TT).
30 function, median reversal measured by dilute thrombin time was 100% within 4 h of idarucizumab admini
31 ram/mL), prolongation of the prothrombin and thrombin times was observed.
32 ed activated partial thromboplastin time and thrombin time, while reducing fibrinogen, coagulation fa